Patients will undergo on-label DBS for the treatment of Parkinson's disease, at stimulator settings different from their usual settings, but within the FDA-approved range for this indication, based on the output of the Bayesian optimization algorithm. Test settings will be evaluated by a brief period of walking on a treadmill which captures measurements of step length. The resulting step length will be provided to the algorithm to inform the next recommended test setting. This will be repeated approximately 30 times to reach putatively optimal DBS settings.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of Parkinson's Disease
DBS in STN or GP (bilateral or unilateral)
At least 3 months after lead implantation
You may not be if
Inability to walk in the off-med, off-stimulation condition (even with safety harness)
Gait impaired significantly by a condition other than PD, as determined by the PI
Breaks or shorts in active contacts
IPG battery nearing end of life (in patients with primary-cell IPGs)
Females who are nursing or pregnant
Diminished capacity to consent (concluded via UBACC)